Innacell gamma-delta therapy

Drug Profile

Innacell gamma-delta therapy

Alternative Names: Innacell GD

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Innate Pharma
  • Class Cell therapies; Small molecules
  • Mechanism of Action Lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Renal cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Renal-cancer in France
  • 12 Jul 2005 Innacell gamma-delta therapy is available for partnering (
  • 29 Jul 2004 Innacell gamma-delta therapy has received orphan drug status for renal cancer in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top